Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.

Autor: Saha A; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Palchaudhuri R; Magenta Therapeutics, Cambridge, MA., Lanieri L; Magenta Therapeutics, Cambridge, MA., Hyzy S; Magenta Therapeutics, Cambridge, MA., Riddle MJ; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Panthera J; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Eide CR; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Tolar J; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Panoskaltsis-Mortari A; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Gorfinkel L; Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA., Tkachev V; Massachusetts General Hospital Center for Transplantation Sciences, Mass General Brigham and Massachusetts General Hospital, Boston, MA., Gerdemann U; Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA., Alvarez-Calderon F; Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA., Palato ER; Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA., MacMillan ML; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Wagner JE; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Kean LS; Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA., Osborn MJ; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Kiem HP; Department of Medicine, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA., Scadden DT; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.; Harvard Stem Cell Institute, Cambridge, MA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA., Olson LM; Magenta Therapeutics, Cambridge, MA., Blazar BR; Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN.

Publikováno v: Blood [Blood] 2024 May 23; Vol. 143 (21), pp. 2201-2216.